Results of a study examining progression free survival at 24 months as a measurement of outcomes in patients with DLBCL.
Home / Resource Library / PROGRESSION-FREE SURVIVAL AT 24 MONTHS AS A LANDMARK AFTER AUTOLOGOUS STEM CELL TRANSPLANT IN RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA